[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders].
The purpose of this article was to study the immunotropic effects of the new neurotrophic heptapeptide selank. The experiments in vitro revealed that the drug in concentration 10-7 M completely suppressed gene expression by peripheral blood IL-6 of patients with depression but not of the healthy controls. At the same time, the significant increase (p<0,05) of IL-6 concentration was observed in the cell culture of peripheral blood of patients in the presence of selank. The changes of the Th1/Th2 cytokine balance in vivo were found in the serum of patients with generalized anxiety disorder and neurasthenia who received Selank during 14 days. The dynamics of these changes had the significant inverse correlation dependence. The cytokine regulating effects revealed in the study suggest that selank can be used as a novel immunomodulator in patients with anxiety-asthenic disorders. Additionally, the adaptogenic properties of selank may be beneficial to its use in elderly people and people exposed to environmental stressors for the prevention of infectious diseases.
Uchakina
O N
ON
Uchakin
P N
PN
Miasoedov
N F
NF
Andreeva
L A
LA
Shcherbenko
V E
VE
Mezentseva
M V
MV
Gabaeva
M V
MV
Sokolov
O Iu
OIu
Zozulia
A A
AA
Ershov
F I
FI
D000328:Adult; D001007:Anxiety / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D001247:Asthenia / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D002478:Cells, Cultured; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D015850:Interleukin-6 / Q000097:blood; D009842:Oligopeptides / Q000627:therapeutic use*; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology*; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology*; D016896:Treatment Outcome
D015850:Interleukin-6; D009842:Oligopeptides; C100827:TP 7